Article Information
History
- April 25, 2018.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yang Li1 (y_li11{at}fudan.edu.cn),
- Fei Wang2 (feiwang{at}cdc.zj.cn),
- Limin Wu3 (2323533220{at}qq.com),
- MIN ZHU4 (zhumindoctor{at}163.com),
- Guiqing He5 (lalaliy{at}sina.com),
- Feng Sun1 (aaronsf1125{at}126.com),
- Qihui Liu1 (08301010265{at}fudan.edu.cn),
- Xiaomeng Wang6,7 (xmwang{at}cdc.zj.cn) and
- Wenhong Zhang1 (zhangwenhong{at}fudan.edu.cn)
- 1 Huashan Hospital, Fudan University, China;
- 2 Zhejiang Provincial Center for Disease Control and Prevention, China;
- 3 Hangzhou Center for Disease Control and Prevention, China;
- 4 Zhejiang Prevention and Treatment Center of Tuberculosis, Zhejiang TCM & WM Hospital, China;
- 5 Wenzhou Center Hospital, China;
- 6 Zhejiang CDC, China
- ↵* Corresponding author; email: xmwang{at}cdc.zj.cn
Posted April 25, 2018.
Cycloserine for Treatment of Multidrug-Resistant Tuberculosis in China: A Retrospective Observational Study
